drugset
drugset / Trial / NCT02496000

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

NCT02496000 ↗

Phase 2 Completed 188 enrolled Oramed, Ltd. Integrium · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled, parallel group study.

Timeline

Start
2015-07-27
Primary completion
2016-06-27
Completion
2016-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ORMD-0801 Protein / enzyme biologic — Oral

Indications

type 2 diabetes mellitus